Professor John Tagg recently spoke with Dave Asprey of Bulletproof Radio about his years of dedicated research and development of BLIS K12TM and BLIS M18TM that began at Otago University and then lead to the establishment of BLIS Technologies.
This insightful podcast talks about how it all began, with John suffering from Group A Strep throat infections as a child and his journey to finding a probiotic solution.
Listen here:
Upper respiratory illnesses, such as the common cold and flu, have a significant impact on our daily lives. To combat these upper respiratory illnesses naturally, a potential solution may be closer than you think: BLIS K12™. T
In our latest whitepaper, shows BLIS M18™ significantly reduces gingivitis in young adults and improved dental health in pre-schoolers that had dental caries, reducing them by 81%.
Halitosis, commonly known as bad breath, can be a persistent and embarrassing problem affecting millions worldwide, with the halitosis treatment market size valued at USD 10.93 billion in 2021…
Halitosis (bad breath) can be a major source of embarrassment and social anxiety for some people. Bad breath is estimated to affect half the adult population at some time, to some extent. BLIS K12™ has been scientifically proven to inhibit bacteria that cause halitosis…
